---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-012791"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T05:41:20.492350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma Reports CC-42344 Shows 1,000-fold Greater Potency Than Tamiflu Against H5N1 Avian Flu

## Summary
- CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
- The PB2 inhibitor targets a highly conserved active site and has shown favorable safety in a Phase 1 study.
- H5N1 has spread in U.S. dairy cattle since March 2024, with rare human cases and low population immunity according to CDC.
- Cocrystal plans further clinical evaluation of CC-42344 for pandemic and seasonal influenza treatment.

## SEC filing metadata
- accession: 0001641172-25-012791
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/0001641172-25-012791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-012791
- JSON: https://secwatch.observer/filing/0001641172-25-012791.json
- Plain text: https://secwatch.observer/filing/0001641172-25-012791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.